We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Troponin Elevation in Acute Ischemic Stroke (TRELAS) (TRELAS)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01263964
First Posted: December 21, 2010
Last Update Posted: July 21, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Christian Nolte, Charite University, Berlin, Germany
December 20, 2010
December 21, 2010
July 21, 2014
February 2011
December 2013   (Final data collection date for primary outcome measure)
culprit lesion on coronary angiogram [ Time Frame: 24 months ]
Same as current
Complete list of historical versions of study NCT01263964 on ClinicalTrials.gov Archive Site
  • transient apical ballooning on levocardiogram [ Time Frame: 24 months ]
  • stroke localization [ Time Frame: 24 months ]
Same as current
Not Provided
Not Provided
 
Troponin Elevation in Acute Ischemic Stroke (TRELAS)
Troponin Elevation in Acute Ischemic Stroke (TRELAS) - a Prospective Study on the Frequency and Correlation to Coronary Artery Disease and to Stroke Localisation
The primary objective of the prospective observational trial TRELAS (TRoponin ELevation in Acute ischemic Stroke) is to elucidate the underlying pathomechanism of cTnT elevation in acute ischemic stroke. Consecutive patients with acute ischemic stroke admitted to the Department of Neurology Campus Benjamin Franklin of the university hospital Charité will be screened for cTnT elevations suggestive of myocardial infarction (>0,05 µg/l). Patients with increased troponin will undergo diagnostic coronary angiography within 72 hours. Diagnostic findings of coronary angiographies taken out in age- and gender-matched patients presenting with NSTE-ACS (Non-ST-Elevation Acute Coronary Syndrome) to the Division of Cardiology will serve as a control. The primary endpoint of the study will be the occurrence of culprit lesions indicating focal cardiac damage on the basis of an acute CAD.
The primary objective of the prospective observational trial TRELAS (TRoponin ELevation in Acute ischemic Stroke) is to elucidate the underlying pathomechanism of cTnT elevation in acute ischemic stroke in order to give guidance for clinical practise. All consecutive patients with acute MRI- or CT-confirmed ischemic stroke admitting within 72 hours after symptom onset to the Department of Neurology Campus Benjamin Franklin of the university hospital of the Charité will be screened for cTnT elevations suggestive of myocardial infarction (>0,05 µg/l) on admission and day 2. Patients with increased troponin will undergo diagnostic coronary angiography within 72 hours. Diagnostic findings of coronary angiographies taken out in age- and gender-matched patients presenting with NSTE-ACS (Non-ST-Elevation Acute Coronary Syndrome) to the Division of Cardiology will serve as a control. The primary endpoint of the study will be the occurrence of angiographic culprit lesions indicating focal cardiac damage on the basis of an acute CAD. Secondary endpoints will be the localisation of stroke in the cerebral imaging and ventriculographic findings of wall motion abnormalities suggestive of neurally mediated global cardiac dysfunction.
Observational
Observational Model: Case Control
Time Perspective: Prospective
Not Provided
Retention:   Samples Without DNA
Description:
Biomarkers indicating myocardial or neuronal damage
Non-Probability Sample
Patients admitted because acute ischemic stroke and additional troponin-elevation(cases) or non-stemi (controlls)
Stroke
Procedure: coronary angiogram
coronary angiogram
  • stroke, troponin elevation
    Patients with stroke (proven by cerebral imaging) and troponin elevation undergoing coronary angiogram
    Intervention: Procedure: coronary angiogram
  • non-stemi (controll group)
    Patients with troponin elevation suggesting non-stemi undergoing coronary angiogram
    Intervention: Procedure: coronary angiogram

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
58
February 2014
December 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Acute ischemic stroke, confirmed by cerebral MRI or CT, respectively
  2. Inclusion within ≤ 72 hours after symptom onset
  3. hsTroponin T >0,05 µg/l

Exclusion Criteria:

  1. Renal insufficiency (creatinine ≥1,2 mg/dl)
  2. Limited life expectancy or mRS ≥ 4 prior to stroke event leading to hospital admission
  3. Contraindications for the coronary angiography
  4. Age < 18 years
  5. Pregnancy
  6. Patient unwilling or unable to give informed consent
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT01263964
EA4/118/10
01 EO 0801 ( Other Grant/Funding Number: German Ministry of Research and Education )
No
Not Provided
Not Provided
Christian Nolte, Charite University, Berlin, Germany
Charite University, Berlin, Germany
Not Provided
Study Director: Matthias Endres, Professor Charite Universitätsmedizin-Berlin
Charite University, Berlin, Germany
July 2014